TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06176768
Drug: LY3972406
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06176768
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06129838
Drug: [11C]-CS1P1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single intravenous bolus injection of 12.0 - 17.0 milliCurie (mCi) of the investigational radiotracer \[11C\]-CS1P1. Participants will then undergo a brain \[11C\]-CS1P1 PET scan
Study: NCT06559150
Drug: Nebulized Placebo Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by a standard jet nebulizer, twice daily for a minimum of 24 weeks and up to a maximum of 156 weeks (3 years)
Study: NCT06122909
Drug: Group VTI
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group VTI will receive resuscitation guided by LVOT-VTI variation after PLR test.
Study: NCT06122909
Drug: Group IVC
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group IVC will receive resuscitation guided by IVC diameter variation after PLR test.
Study: NCT00486772
Drug: Sevelamer (Renagel), calcium acetate (Phos-ex)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04117165
Drug: Patient Current Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: The rheumatologist will use the french guidelines of rheumatoid arthritis to choose the more adapted biotherapy treatment to the patient.
Study: NCT04970355
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-filled syring; s.c. injection
Study: NCT06381063
Drug: pain management
Normalized name: Olu Pain Management 4%-1% Topical Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: o Pain management in both arms Intraoperative time: intravenous ketamine 0.5 mg kg-1, intravenous dexamethasone 8 mg Postoperative time: paracetamol 1 g every 6 hours a day, nefopam 20 every 8 hours a day, patient control analgesia with morphine or oxycontin
Study: NCT06381063
Drug: ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen 100 mg twice a day, during 48 after surgery, intravenous administration
Study: NCT06381063
Drug: PLacebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice a day, during 48 h after surgery, intravenous administration
Study: NCT05368623
Drug: Mydriatic Agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological dilation of pupils will be done by instilling mydriatic agent in eyes of Subjects
Study: NCT05460065
Drug: single E4 30 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a single intravenous (i.v.) infusion of estetrol (E4) 30 mg (n=6)
Study: NCT05460065
Drug: single E4 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a single i.v. infusion of E4 100 mg (n=6)
Study: NCT05460065
Drug: multiple E4 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of an i.v. infusion of E4 100 mg (or lower dose, depending on single dose results) once a day for 5 consecutive days (n=8)
Study: NCT05460065
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort A: Single dose of placebo (n=2);~Cohort B: Single dose of placebo (n=2);~Cohort C: multiple dose of placebo (n=4)
Study: NCT06442280
Drug: Hypertonic Saline Solution, 1 Ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of furosemide combined with hypertonic saline solutions (100 mL) twice daily
Study: NCT06224400
Drug: ENC1018 for MAD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (cohort B1-B3) to receive either ENC1018 or placebo. The investigational product (ENC1018 or placebo) will be administered orally for a total of 14 days.
Study: NCT06246175
Drug: HRS9531
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive a single dose of HRS9531 injection
Study: NCT05456269
Drug: Decitabine and cedazuridine
Normalized name: cedazuridine / decitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO fixed-dose decitabine/cedazuridine 35/100 mg tablet daily for 5 days (Days 1 to 5), 1 hour prior bisantrene infusion
Study: NCT05221580
Drug: Ryzodeg®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with commercially available Ryzodeg® in a prefilled device (FlexTouch®) or in a penfill according to the label and routine clinical practice at the discretion of the treating physician
Study: NCT05812404
Drug: DWP14012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium-competitive acid blocker
Study: NCT05812404
Drug: DWC202201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin Calcium Trihydrate
Study: NCT05253846
Drug: Lederfolin
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment
Study: NCT05306418
Drug: Mim8
Approvals — FDA: no, EMA: no, PMDA: no
Description: For treatment part 1, all participants will start on once-weekly treatment and continue on this regimen until week 26. For treatment part 2, starting at week 26, all participants will be offered the choice to remain on once-weekly or switch to once-monthly dosing.~Mim8 will be injected with a thin needle into the skin
Study: NCT04879628
Drug: placebo IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution Route of administration: IV infusion
Study: NCT04879628
Drug: placebo SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution Route of administration: SC injection
Study: NCT05903820
Drug: Estradiol patch
Normalized name: Estradiol Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal patch of estradiol
Study: NCT02233257
Drug: Lorenzo's Oil
Normalized name: LORENZO'S OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral use of Lorenzo's oil to lower very long chain fatty acids
Study: NCT05793736
Drug: Treatment as usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The sample will be treated only with standard therapies (treatment as usual) without the use of biofeedback training
Study: NCT05324735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive placebo (orally ingested) twice a day for 12 weeks.
Study: NCT04972656
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet (one to two tablets corresponding to one to two verum tablets).~Administration:~Placebo will be administrated orally with or without food intake in the morning.
Study: NCT05251493
Drug: Iron Isomaltoside 1000, ferric derisomaltose
Approvals — FDA: no, EMA: no, PMDA: no
Description: iron isomaltoside 20 mg/mL
Study: NCT05984537
Drug: standard heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the standard heparin group received a one-time intravenous injection of 50 U/kg of standard heparin during PCI.
Study: NCT04909723
Drug: NB2000P
Approvals — FDA: no, EMA: no, PMDA: no
Description: A botanically derived polysaccharide.
Study: NCT04909723
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06193135
Drug: Folitropin Beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will receive daily dose of Folitropin Beta since triggering criteria are met.
Study: NCT04807413
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The balloon will be opened to deliver nitric oxide at 40 ppm through the cardiopulmonary bypass machine
Study: NCT04810962
Drug: APP13007, 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: APP13007 eye drop, 0.05%
Study: NCT04810962
Drug: Matching Vehicle Placebo for APP13007, 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching vehicle placebo eye drop
Study: NCT06135714
Drug: Systemic therapy for 12 weeks after primary registration
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Luminal BC~  1. Denovo stage IV~     Premenopausal(PRE): Aromatase inhibitor(AI) + CDK4/6 inhibitor(CDK) +LHRH agonist, or Fulvestrant(FUL) + CDK4/6 inhibitor +LHRH agonist~     Postmenopausal(POST): AI + CDK~ 2. Recurrence after completion of postoperative endocrine therapy~     PRE: AI + CDK +LHRH agonist, or FUL + CDK +LHRH agonist~     POST: AI + CDK, or FUL + CDK~ 3. Recurrence during postoperative endocrine therapy~     PRE: FUL + CDK +LHRH agonist, or AI + CDK +LHRH agonist~     POST: FUL + CDK~* HER2-positive BC~Pertuzumab + Trastuzumab + Taxane (docetaxel or paclitaxel)~・Triple negative BC.~1. PD-L1 negative - following a) or b)~   1. Taxane (naive for taxane)~  2. S-1 or Capecitabine or Eriblin (previously treated with taxane)~2. PD-L1 positive - following a) or b)~   1. Pembrolizumab + Gemcitabine + Carboplatin~  2. Atezolizumab + Nab-paclitaxel~3. BRCA-mutation positive Olaparib
Study: NCT06135714
Drug: Same systemic therapy after secondary registration
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Luminal BC~  1. Denovo stage IV~     Premenopausal(PRE): Aromatase inhibitor(AI) + CDK4/6 inhibitor(CDK) +LHRH agonist, or Fulvestrant(FUL) + CDK4/6 inhibitor +LHRH agonist~     Postmenopausal(POST): AI + CDK~ 2. Recurrence after completion of postoperative endocrine therapy~     PRE: AI + CDK +LHRH agonist, or FUL + CDK +LHRH agonist~     POST: AI + CDK, or FUL + CDK~ 3. Recurrence during postoperative endocrine therapy~     PRE: FUL + CDK +LHRH agonist, or AI + CDK +LHRH agonist~     POST: FUL + CDK~* HER2-positive BC~Pertuzumab + Trastuzumab + Taxane (docetaxel or paclitaxel)~・Triple negative BC.~1. PD-L1 negative - following a) or b)~   1. Taxane (naive for taxane)~  2. S-1 or Capecitabine or Eriblin (previously treated with taxane)~2. PD-L1 positive - following a) or b)~   1. Pembrolizumab + Gemcitabine + Carboplatin~  2. Atezolizumab + Nab-paclitaxel~3. BRCA-mutation positive Olaparib
Study: NCT05463861
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match Lemborexant tablet administered orally once daily.
Study: NCT05991661
Drug: XKH001 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg/ml，1ml/vial
Study: NCT05991661
Drug: XKH001 Placebo Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1ml/vial
Study: NCT05700591
Drug: rhPro-UK
Normalized name: Vital E- Repro
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg, administered intravenously with a bolus of 15 mg within 3 minutes and the remainder by continuous infusion within 30 minutes
Study: NCT05733572
Drug: CHF6467
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug eyedrops
Study: NCT05733572
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo eyedrops
Study: NCT05939674
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: During induction, patients will receive remimazolam 6mg/kg/h with remifentanil TCI 1\~4 nanogram/mL. After patient loses consciousness, anesthesia will be maintained with remimazolam 1-2mg/kg/h combined with remifentanil. When procedure ends, infusion remimazolam stops and 0.9% normal saline according to allocated groups.
Study: NCT04083170
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05998863
Drug: EffCaMgCit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each sachet of EffCaMgCit will contain 19 meq or 380 mg calcium, 10 meq (122 mg) magnesium, and 50 meq total citrate.
Study: NCT04939116
Drug: ANG-3070
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered tyrosine kinase inhibitor capsule
Study: NCT04939116
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered placebo capsule
Study: NCT05658120
Drug: noradrenaline/adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: norepinephrine adrenaline in patients with Swan-Ganz catheter monitoring during liver transplantation
Study: NCT05248867
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution for injection
Study: NCT05248867
Drug: AGN-151586
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN-151586 solution for injection
Study: NCT05035654
Drug: LYR-220 Design 2 (Part 1 and Part 2)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LYR-220 drug matrix (mometasone furoate 7500 µg) Design 2
Study: NCT05035654
Drug: Bilateral sham procedure control (Part 2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral sham procedure control
Study: NCT00012857
Drug: acetaminophen 650 mg qid and placebo qid PRN. The other arm was placebo qid and acetaminophen 650 mg qid PRN
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05664737
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT04711005
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be made up of a 0.9% w/v saline solution (53 mL total volume) administered via slow IV infusion over a 40-minute period.
Study: NCT05201690
Drug: VV116 200 mg Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: VV116 9 subjects will receive VV116 200 mg, orally, QD12h, 5.5 days ;
Study: NCT05201690
Drug: VV116 400mg Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: VV116 9 subjects will receive VV116 400 mg, orally, QD12h, 5.5 days ;
Study: NCT05201690
Drug: VV116 600mg Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: VV116 9 subjects will receive VV116 600 mg, orally, QD12h, 5.5 days ;
Study: NCT05065645
Drug: Angiotensin Converting Enzyme 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD: single dose; MAD: dosage 2x daily for 7 days
Study: NCT04999787
Drug: HSK21542
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK21542-0.3 μg/kg，HSK21542-0.6 μg/kg
Study: NCT04999787
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05641909
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil
Study: NCT05641909
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosage forms and strengths: 50 mcg/mL Fentanyl base/10 mL ampules. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd
Study: NCT04799990
Drug: Comparator 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, Opthalmic, Subcutaneous or Intravenous Injection
Study: NCT05525468
Drug: TDM-180935
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDM-180935 topical ointment
Study: NCT05525468
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for TDM-180935 topical ointment
Study: NCT05875571
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will get IV ketorolac during IUD placement under sedation
Study: NCT05875571
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will get IV placebo during IUD placement under sedation
Study: NCT06134622
Drug: Intravenous thrombolysis plus placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (saline)
Study: NCT05413642
Drug: Recommended treatment schedule
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory drugs (NSAIDs) Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle oxygen therapy
Study: NCT05413642
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment regimens different from the recommended one according to family physician personal practice
Study: NCT04808544
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzyl benzoate and sesame oil served as placebo solution (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
Study: NCT05944887
Drug: Saline administration as placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of a bolus of saline solution as a placebo
Study: NCT03629093
Drug: General Anesthetics
Normalized name: GENERAL ANESTHETICS,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia required for surgery procedures or diagnostic interventions using either intravenous or inhalation anesthetics, or both.
Study: NCT04424602
Drug: cyclo phosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg vial
Study: NCT04655599
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olorinab matching placebo tablet by mouth, 3 times a day for 4 days with a final dose on Day 5.
Study: NCT05638087
Drug: Placebo Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral Mix
Study: NCT04660539
Drug: azathioprine (AZA)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants are permitted to use AZA during the study as background immunosuppressive treatment at a maximum dose of 3 milligram per kilogram per day (mg/kg/day)
Study: NCT04660539
Drug: oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are permitted to use oral corticosteroids (prednisolone equivalent) during the study as background immunosuppressive treatment at a maximum dose of 15 mg/day
Study: NCT06670170
Drug: PF-07976016 Formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-07976016; Formulation B - new/test
Study: NCT06310551
Drug: Oral VH4524184
Approvals — FDA: no, EMA: no, PMDA: no
Description: VH4524184 to be taken orally.
Study: NCT06310551
Drug: Placebo Formulation A SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose of Placebo Formulation A administered subcutaneously.
Study: NCT06310551
Drug: rHuPH20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of rHuPH20 administered subcutaneously.
Study: NCT06310551
Drug: VH4524184 Formulation B SC
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose of VH4524184 LAI Formulation B administered subcutaneously.
Study: NCT06310551
Drug: Placebo Formulation B SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose of Placebo Formulation B administered subcutaneously.
Study: NCT06310551
Drug: Placebo Formulation C SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of Placebo Formulation C administered subcutaneously.
Study: NCT06310551
Drug: Placebo Formulation A IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of Placebo Formulation A administered intramuscularly.
Study: NCT06310551
Drug: VH4524184 Formulation B IM
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose VH4524184 LAI Formulation B administered intramuscularly.
Study: NCT06310551
Drug: Placebo Formulation B IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of Placebo Formulation B administered intramuscularly.
Study: NCT06028230
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT05237596
Drug: Glucosamine Sulfate
Normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for at least 6 months with prescription-grade crystalline Glucosamine Sulfate in addition to conventional treatment
Study: NCT05786066
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered 2.5 hours before Ketamine infusion
Study: NCT05167864
Drug: Onabotulinumtoxina for Injection
Normalized name: Onabotulinumtoxina for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: cosmetic injection into the glabella area (eyebrow area)
Study: NCT05167864
Drug: PrabotulinumtoxinA for Injection
Normalized name: prabotulinumtoxinA-xvfs
Approvals — FDA: no, EMA: no, PMDA: no
Description: cosmetic injection into the glabella area (eyebrow area)
Study: NCT04852003
Drug: SHR0410 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR0410 Injection
Study: NCT04852003
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for SHR0410 Injection
Study: NCT05780541
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially available 0.9% sodium chloride solution
Study: NCT06259526
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: (1 pill of 25 mg JS1-1-01 placebo pills +1 pill of 50 mg JS1-1-01 placebo pills+1 pill of duloxetine hydrochloride placebo capsule)/time, 2 times per day, administered postprandial, for 8 consecutive weeks.
Study: NCT06259526
Drug: JS1-1-01 high-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: (1 pill of 25 mg JS1-1-01 pills +1 pill of 50 mg JS1-1-01 pills +1 pill of Duloxetine hydrochloride placebo capsule)/time, 2 times per day, administered postprandial, for 8 consecutive weeks.
Study: NCT05786417
Drug: Beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selection of the specific BB and initial starting dose will be determined by the treating clinician.
Study: NCT05786417
Drug: Calcium channel blocker
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selection of the specific CCB and initial starting dose will be determined by the treating clinician.
Study: NCT05880043
Drug: GIC-102
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIC-102 will be administered via IV infusion 3 times at intervals of 1 week, and 28 days is defined as 1 cycle
Study: NCT04729517
Drug: AI201901
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily inhaled AI201901 for 4 weeks
Study: NCT06240390
Drug: pharmacological treatment by Opioids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid analgesics are the main option for pain treatment in cancer patients, but their side effects and inadequate treatment lead to cheaper, quicker options with lower risk of addiction and/or side effects.
Study: NCT05326516
Drug: Chemotherapy Regimen 1
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 2 treatment cycles of chemotherapy. During Cycle 1, participants will receive prednisone, vincristine, pegaspargase/calaspargase pegol-mknL, and daunorubicin. During Cycle 2, participants will receive etoposide and cyclophosphamide.
Study: NCT05326516
Drug: Chemotherapy Regimen 2
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 2 treatment cycles of chemotherapy. During Cycles 1 and 2, participants will receive fludarabine and cytarabine.
Study: NCT06361433
Drug: HUFF-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: autologous MSC combined with scaffold
Study: NCT04798755
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inicial dose 15mg/week increasing up to 25 mg/week